Afatinib Targeted Therapy Affects the Immune Function and Serum Levels of EGFR and Gastrin-Releasing Peptide Precursor (pro-GRP) in Patients with Non-Small-Cell Lung Cancer (NSCLC)

Table 3

Comparing the immune function indexes of the two groups of patients before and after intervention.

Group	Treatment group A ()	Treatment group B ()
CD3^+
Before intervention			5.06/4.14	0.02/0.01
After intervention	^
CD4^+
Before intervention			4.57/6.22	0.03/0.01
After intervention	^
CD8^+
Before intervention			4.33/6.76	0.02/0.01
After intervention	^
CD4^+/CD8^+
Before intervention			5.02/5.21	0.02/0.01
After intervention	^

Note: and are time statistics; and are between-group factor statistics; compared with treatment group A, ; compared with before intervention, ^.